Seventy neonatal to adolescent general surgical patients were studied to create an individual dose-response curve for the long-acting neuromuscular blocking agents, alcuronium and d-tubocurarine. The mean (SEM) ED95 of alcuronium was 196 (9), 271 (13) and 243 (8) Jlglkg in infants, children and adolescents, respectively (P < 0.01). d-tubocurarine showed a similar age dependent dose-response relationship. ED95 doses were 414 (40), 499 (41) and 445 (31) Jlglkg, respectively. The onset time (time from intravenous administration to maximal effect) following equipotent dosages was 40-50% shorter in infants than in children or adolescents (1.5 vs 2.7 minutes, P < 0.05).
When alcuronium is used during paediatric anaesthesia to induce or maintain neuromuscular block, dosing is based solely on clinical experience. There are no published data on the dose-response relationship of alcuronium in paediatric patients. Recent studies indicate that the dose requirement of vecuronium, pancuronium and atracurium is significantly influenced by the age of a paediatric patient. lA The purpose of this study was to determine if the doses of alcuronium required to establish a 50% and a 95% neuromuscular block are similarly influenced by age. The results were compared to the existing studies on the other muscle relaxants and to the dose-response results of d-tubocurarine.
PATIENTS AND METHODS Seventy general surgical paediatric patients were selected for the study on the basis of their age, following Institutional Ethical Committee approval. Patients were premedicated with oral chloral hydrate 40 mg/kg or diazepam 0.25 mglkg. General anaesthesia was induced by sodium thiopentone 4-6 mg/kg and nitrous oxide in oxygen 2: 1. Ventilation was controlled by face mask with a T-piece or a Bain circuit. Palmar skin temperature was maintained higher than 34°C.
Electromyographic recording was used to assess the neuromuscular block (Relaxograph® , Datex, Helsinki, Finland, software 873267-03). Stimulating surface electrodes were attached over the ulnar nerve at the wrist and recording electrodes over the adductor pollicis muscle and base of the middle finger when the patient was fully anaesthetized. Train-of-four supramaximal square wave stimuli of 0.1 msec duration were used at 2Hz every 20 sec. Patients received incremental doses of either alcuronium (cumulative doses of 80, 120, 180 and 270 Ilglkg) or d-tubocurarine (cumulative doses of 120, 180,270 and 400 Ilglkg) following the calibration 'and stable response' of the electromyograph. Neuromuscular block was determined as the percentage depression of the first twitch height in the train-of-four series of responses. Incremental doses were given when the EMG twitch responses became unchanged aftera previous dose. The final incremental dose was individually estimated to establish a 95% neuromuscular block when twitch height was depressed by > 70%. 5 Alcuronium dose-response was measured in four groups of ten patients: less than a year old, from one to less than five years old, from five to less than ten years old, and from twelve to less than sixteen years old. d-tubocurarine dose-response was measured in three groups often patients: less than two years old, from three to less than ten years old and from twelve to less than sixteen years. Endotracheal intubation was carried out in each patient when a > 90% neuromuscular block had been established.
The onset time (time from intravenous administration to maximal effect) was analyzed for each patient following the incremental dose which produced a > 70% neuromuscular block.
The percentage neuromuscular block was transformed to probit values and the cumulative doses to logarithm values. The conversion of the dose response data to a log probit plot has been shown to produce a linear dose-response curve in both single dose and cumulative dose-response studies. 6 Thereafter a linear regression analysis was performed to calculate the effective doses and the slopes of the individual dose-response curves.! The values are presented as mean (SEM). Mean values of different age groups were compared by using analysis of variance with Bonferroni correction. A P-value of < 0.05 was considered significant. Table 1 . The linear regression lines of the log-probit doseresponse curves expressed squared correlation coefficients (c 2 ) of 0.995 (0.001). This confirms the linear relationship between the log-dose and probit-response in the range of 1-99% responses. 6 The dose-response curves were parallel among all age groups for both muscle relaxants studied ( Table   2 ).
RESULTS

Patient characteristics are shown in
The ED50 and ED95 doses ofalcuronium were 38 and 24% greater in children and in adolescents, respectively, than in infants (P < 0.0l). The ED-values for d-tubocurarine were related to the age of the patient by a lesser degree. Due to great individual variability of the ED-values of d-tubocurarine, the differences between the age groups did not become significant. The onset times were measured following equipotent doses of alcuronium and d-tubocararine, given when neuromuscular blockade was about 50%. These increments produced an average of 85% block in each group. Onset times were shortest in infants and longest in adolescents (1.5 vs. 2.7 minutes, P < 0.01). The onset times were comparable for both muscle relaxants studied ( Table 2) . DISCUSSION This study shows that children require a greater dose of alcuronium or d-tubocurarine to establish comparable level of neuromuscular block than either infants or adolescents. Similar agedependency has been documented for atracurium, vecuronium and pancuronium.!·4 Comparison of the present results to adult data derived from EMG monitoring show that the adult dose-requirement for alcuronium (ED95 of 190-240 ~g1kg) is comparable to adolescent or infant requirements. 7, 8 It seems logical that the infant's requirement for a non-depolarizing muscle relaxant is comparable with the adult requirement: the infant's sensitive neuromuscular junction 9 and large distribution volume (extracellular fluid volume)lO counteract each other to result in comparable ED-values (effective plasma concentration times distribution volume). This explanation, however, doses not clarify children's greater dose-requirements. Differences in the body composition during growth of paediatric patients may explain different children's dose-requirements. After the first year oflife and before adolescence, there are major changes in the fat and muscle compartments of the human body although the extracellular fluid volume remains relatively constant.11 Fat constitutes as much as 30% of body weight at one year of age. Thereafter this compartment diminishes towards puberty. The muscle compartment is small at one year of age and increases several fold to a maximum of 40% of body weight by the end of active growth of a child. If muscular activity is limited, then this muscle compartment diminishes and fat compartment increases during adulthood. It would be logical to suggest that a child, with a relatively large muscle compartment, will require more muscle relaxants to block neuromuscular transmission than infants or adults. Children may also require greater plasma concentration of muscle relaxant than adults to develop comparable muscle paralysis. 10
Different age-dependent dose requirements for long-acting muscle relaxants are clinically even more important than differences for intermediateacting muscle relaxants. If twice the dose actually required for the individual is administered, then the duration of effect is extended by approximately one elimination half-life of that agent. In the case of long-acting muscle relaxants this prolongation would make it difficult to reverse the residual neuromuscular block at the end of a short anaesthetic. 12 Unless prolonged surgery is anticipated, we would recommend the use of doses of alcuronium and d-tubocurarine in doses close to their ED 95 . The recommendations for alcuronium would be 0.2 and 0.3 mg/kg for infants and children respectively. For d-tubocurarine it would be 0.4 and 0.5 mglkg respectively. In 10% of patients, these doses are less than ED 90 ' In these patients, anaesthesia should be deepened or a small increment of relaxant will be needed for easy intubation.
Shorter onset times of these muscle relaxants in infancy, compared to any older age group, are most probably related to the faster circulation of infants. This results from shorter absolute distances and greater cardiac output. Human infants have cardiac outputs of 180-240 mllkg/min, as compared to adult value of 70 mllkg/min. 13 Therefore, infants circulate the equivalent of their blood volume (80 mllkg) in 20-25 seconds, as opposed to 60 seconds in adults with a blood volume of 70 mllkg. Infants also have short onset times for other muscle relaxants. [2] [3] To sum up, we found clinically important agedependent variation in the dose requirement of Anaesthesia and Intensive Care. Vol. 18. No. 4, November, 1990 alcuronium for paediatric patients in different age groups. Infants require a comparable dose to adolescents and adults, but children require a greater dose. The onset time of muscle relaxants is shortest in infancy.
